Together, we used in vitro motility assays and in vivo models to confirm that TGX221 selectively inhibited RCC cells with VHL and SETD2 mutations and conferred inhibition to tumourigenesis of RCC with mutated target genes. This evidence concerns the gene VHL and renal cell carcinoma.